DENTSPLY SIRONA Inc. (NASDAQ: XRAY) stock fell -0.19% on Friday to $30.78 against a previous-day closing price of $30.84. With 6.04 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.86 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $31.54 whereas the lowest price it dropped to was $30.78. The 52-week range on XRAY shows that it touched its highest point at $61.18 and its lowest point at $30.58 during that stretch. It currently has a 1-year price target of $42.70. With its current market cap of 6.82 billion, XRAY has annualized dividend of $0.50 while the current yield stands at 1.62%. Beta for the stock currently stands at 0.92.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of XRAY was down-trending over the past week, with a drop of -5.47%, but this was down by -10.70% over a month. Three-month performance dropped to -13.37% while six-month performance fell -38.04%. The stock lost -48.08% in the past year, while it has lost -44.83% so far this year. A look at the trailing 12-month EPS for XRAY yields 1.68 with Next year EPS estimates of 2.65. For the next quarter, that number is 0.54. This implies an EPS growth rate of 604.90% for this year and 10.81% for next year. EPS is expected to grow by 5.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -0.30%.
Float and Shares Shorts:
At present, 217.80 million XRAY shares are outstanding with a float of 214.56 million shares on hand for trading. On Jul 14, 2022, short shares totaled 6.81 million, which was 3.16% higher than short shares on Jun 14, 2022. In addition to Mr. Walter Petersohn as the firm’s Sr. VP & Chief Commercial Officer, Mr. John P. Groetelaars serves as its Interim CEO & Director.
Through their ownership of 101.93% of XRAY’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 58.67% of XRAY, in contrast to 40.52% held by mutual funds. Shares owned by individuals account for 1.47%. As the largest shareholder in XRAY with 10.94% of the stake, The Vanguard Group, Inc. holds 23,574,362 shares worth 23,574,362. A second-largest stockholder of XRAY, Artisan Partners LP, holds 12,758,726 shares, controlling over 5.92% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in XRAY, holding 11,101,292 shares or 5.15% stake. With a 2.95% stake in XRAY, the Vanguard Total Stock Market Index is the largest stakeholder. A total of 6,364,442 shares are owned by the mutual fund manager. The First Eagle Global Fund, which owns about 2.87% of XRAY stock, is the second-largest Mutual Fund holder. It holds 6,187,890 shares valued at 202.78 million. Vanguard Mid Cap Index Fund holds 2.30% of the stake in XRAY, owning 4,946,860 shares worth 162.11 million.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, XRAY reported revenue of $965.00M and operating income of $96.00M. Over the past year, revenue came in at $4.19B while operating income stood at $561.00M. It generated $65.00M net income for the quarter, which came to $369.00M over the last twelve months. The EBITDA in the recently reported quarter was $182.00M and diluted EPS was $0.30. EBITDA for the full year was $899.00M.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for XRAY since 9 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 4 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With XRAY analysts setting a high price target of $51.00 and a low target of $38.00, the average target price over the next 12 months is $42.50. Based on these targets, XRAY could surge 65.69% to reach the target high and rise by 23.46% to reach the target low. Reaching the average price target will result in a growth of 38.08% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. XRAY will report FY 2022 earnings on 02/27/2023. Analysts have provided yearly estimates in a range of $2.47 being high and $2.28 being low. For XRAY, this leads to a yearly average estimate of $2.39. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. DENTSPLY SIRONA Inc. surprised analysts by $0.05 when it reported $0.60 EPS against a consensus estimate of $0.55. The surprise factor in the prior quarter was -$0.04. Based on analyst estimates, the high estimate for the next quarter is $0.66 and the low estimate is $0.54. The average estimate for the next quarter is thus $0.61.
Dividends & Yield:
In terms of dividends, XRAY has a current ratio of $0.5, which is $0.5 over the trailing 12-months, while a dividend of $0.38 is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and XRAY currently yields $1.53. In the past year, XRAY’s dividend yield has been $1.53, but when looking at the stock over the past five years, its yield has been $0.79. Accordingly, XRAY has a current buyback yield of $3.92. This was $3.92 for the TTM, and it was $2.57 for the past five years.
Summary of Insider Activity:
Insiders traded XRAY stock several times over the past three months with 11 Buys and 2 Sells. In these transactions, 329 shares were bought while 243 shares were sold. The number of buy transactions has increased to 105 while that of sell transactions has risen to 51 over the past year. The total number of shares bought during that period was 698,883 while 415,301 shares were sold.